Petosemtamab + Pembrolizumab: Dual EGFR & LGR5 Targeting Yields 60% ORR in PD-L1+ r/mHNSCC

In this Phase 2 trial, treatment of 43 evaluable r/m PD-L1+ HNSCC patients with petosemtamab 1500 mg Q2W plus pembrolizumab produced a 60% overall response rate (5 complete responses; 11%) and a median duration of response of 11 months. The 6‐month overall survival rate was 93%, with manageable, predominantly Grade 1/2 adverse events and infusion-related reactions primarily at first infusion. Compared to pembrolizumab monotherapy (KEYNOTE-048 trial) ORR of 17% and CR of 5% makes this combo look even better!